Free 2 day AUS and US shipping for orders above $200 • Register for an account to receive 20% off

CJC-1295 (No DAC) / Ipamorelin Blend (5mg/5mg)

CJC-1295 (No DAC) / Ipamorelin Blend (5mg / 5mg)

$75.00

The CJC-1295 (No DAC) / Ipamorelin blend (5mg/5mg) (is designed for research on stimulating natural growth hormone (GH) and IGF-1 secretion. This synergistic combination acts through two distinct but complementary pathways, offering a balanced and sustained approach to growth hormone release — often studied for its potential in cellular repair, recovery, and anti-aging research. CJC-1295 (No DAC): A synthetic analog of growth hormone-releasing hormone (GHRH) that binds to receptors on the pituitary gland to stimulate GH secretion. The No DAC version has a shorter duration, allowing researchers to study more precise, natural GH pulse patterns without prolonged elevation. Ipamorelin: A selective growth hormone secretagogue (GHS) that mimics ghrelin’s GH-releasing activity. It triggers pulsatile GH release without raising cortisol or prolactin — ideal for controlled, balanced research conditions. When combined, CJC-1295 and Ipamorelin create a dual-phase GH release: CJC-1295 provides the sustained background stimulation, while Ipamorelin adds natural rhythmic pulses — a synergistic model for optimizing GH release.  

Synergistic Summary

  • Comprehensive Tissue Regeneration: Multi-tissue repair and accelerated wound healing
  • Aesthetic and Skin Health Benefits: Improved skin elasticity and reduced scarring
  • Powerful Antioxidant and Cytoprotective Properties: Cellular protection and reduced oxidative stress
  • Enhanced Angiogenesis: Improved blood flow and nutrient delivery
  • Broad-Spectrum Anti-Inflammatory Effects: Reduced inflammation and pain
  • Improved Connective Tissue Strength: Enhanced collagen production and matrix remodeling
  • Accelerated Muscle and Tendon Repair: Faster recovery from injuries
  • Overall Systemic Healing: Enhanced recovery from various forms of cellular damage

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

In Stock
Research Summary Description
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse Summary: This study demonstrated that once-daily administration of CJC-1295 (without DAC) was able to normalize body weight and length in GHRH knockout mice. This effect was accompanied by an increase in total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation.

Citation: Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
What is CJC1295 without DAC? Summary: This article highlights that CJC1295 without DAC has a relatively short half-life, typically around 30 minutes to an hour. This contrasts sharply with the DAC-modified version, which can have a half-life of 6 to 8 days due to its binding to albumin.

Citation: Bocsci. (n.d.). What is CJC1295 without DAC?
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Summary: This study, which introduced CJC-1295 (the DAC version), noted that the first 29 amino acids of GHRH (sermorelin) were as potent as the full 44-amino acid structure, but had rapid metabolic clearance. This led to the development of analogues like Modified GRF (1-29) to enhance biological activity and reduce rapid metabolic clearance.

Citation: Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.,... & Abribat, T. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Summary: While this study primarily focuses on CJC-1295 with DAC, it is foundational to understanding the broader family of GHRH analogs, including the principles behind CJC-1295 no DAC. This randomized, placebo-controlled, double-blind study in healthy adults (ages 21-61) demonstrated that subcutaneous administration of CJC-1295 (DAC) led to sustained, dose-dependent increases in mean plasma GH concentrations (2- to 10-fold for 6 days or more) and IGF-I concentrations (1.5- to 3-fold for 9-11 days). The estimated half-life of CJC-1295 (DAC) was 5.8-8.1 days. It was found to be safe and relatively well tolerated. This study implies the potential for GHRH analogs to impact GH and IGF-I levels.

Citation:
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, R., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats Summary: This study demonstrated that Ipamorelin dose-dependently increased the longitudinal bone growth rate (LGR) and body weight gain in adult female rats.

Citation: Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus Summary: This study showed that Ipamorelin accelerated gastric emptying and intestinal transit in a rodent model of postoperative ileus (POI). This effect is mediated by its action on ghrelin receptors located on cholinergic neurons in the gut.

Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534.
Ipamorelin, the first selective growth hormone secretagogue Summary: This study identified Ipamorelin as the first selective growth hormone secretagogue. This selectivity means it stimulates GH release without significantly affecting other hormones like adrenocorticotropic hormone (ACTH) and cortisol, unlike some other GH-releasing peptides.

Citation: Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
The benefits of Ipamorelin growth hormone Summary: This article states that Ipamorelin increases growth hormone levels by stimulating the hypothalamus, leading to increased muscle mass and strength, as well as fat loss due to increased metabolism and lipolysis. It also notes benefits such as improved workouts and recovery, reduced body fat, increased energy, and deeper sleep.

Citation: NYMD Center. (n.d.). The Benefits of Ipamorelin Growth Hormone.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

Summary: This study demonstrated that once-daily administration of CJC-1295 (without DAC) was able to normalize body weight and length in GHRH knockout mice. This effect was accompanied by an increase in total pituitary RNA and GH mRNA, suggesting somatotroph cell proliferation.

Citation: Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.

What is CJC1295 without DAC?

Summary: This article highlights that CJC1295 without DAC has a relatively short half-life, typically around 30 minutes to an hour. This contrasts sharply with the DAC-modified version, which can have a half-life of 6 to 8 days due to its binding to albumin.

Citation: Bocsci. (n.d.). What is CJC1295 without DAC?

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

Summary: This study, which introduced CJC-1295 (the DAC version), noted that the first 29 amino acids of GHRH (sermorelin) were as potent as the full 44-amino acid structure, but had rapid metabolic clearance. This led to the development of analogues like Modified GRF (1-29) to enhance biological activity and reduce rapid metabolic clearance.

Citation: Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I.,... & Abribat, T. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058.

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Summary: While this study primarily focuses on CJC-1295 with DAC, it is foundational to understanding the broader family of GHRH analogs, including the principles behind CJC-1295 no DAC. This randomized, placebo-controlled, double-blind study in healthy adults (ages 21-61) demonstrated that subcutaneous administration of CJC-1295 (DAC) led to sustained, dose-dependent increases in mean plasma GH concentrations (2- to 10-fold for 6 days or more) and IGF-I concentrations (1.5- to 3-fold for 9-11 days). The estimated half-life of CJC-1295 (DAC) was 5.8-8.1 days. It was found to be safe and relatively well tolerated. This study implies the potential for GHRH analogs to impact GH and IGF-I levels.

Citation:
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, R., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Summary: This study demonstrated that Ipamorelin dose-dependently increased the longitudinal bone growth rate (LGR) and body weight gain in adult female rats.

Citation: Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.

Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus

Summary: This study showed that Ipamorelin accelerated gastric emptying and intestinal transit in a rodent model of postoperative ileus (POI). This effect is mediated by its action on ghrelin receptors located on cholinergic neurons in the gut.

Citation: Beck, D. E., Sweeney, W. B., & McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534.

Ipamorelin, the first selective growth hormone secretagogue

Summary: This study identified Ipamorelin as the first selective growth hormone secretagogue. This selectivity means it stimulates GH release without significantly affecting other hormones like adrenocorticotropic hormone (ACTH) and cortisol, unlike some other GH-releasing peptides.

Citation: Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.

The benefits of Ipamorelin growth hormone

Summary: This article states that Ipamorelin increases growth hormone levels by stimulating the hypothalamus, leading to increased muscle mass and strength, as well as fat loss due to increased metabolism and lipolysis. It also notes benefits such as improved workouts and recovery, reduced body fat, increased energy, and deeper sleep.

Citation: NYMD Center. (n.d.). The Benefits of Ipamorelin Growth Hormone.

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping
20% OFF